BetterLife Pharma hires Syner-G to oversee GMP manufacturing of BETR-001 for IND, Phase 1

Better Home & Finance

Better Home & Finance

BETR

0.00
  • BetterLife signed an agreement with Syner-G BioPharma Group to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program.
  • BETR-001 is projected to file an IND and start Phase 1 trials in Q1 2027.
  • Separate marketing-services engagement signed with GTM Studios for two months at $4,000 per month.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.